Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
26 February 2019 | Story Eugene Seegers | Photo Eugene Seegers
Prof Francis Petersen, Rector and Vice-Chancellor, Prof Daniella Coetzee, South Campus Principal, Tshegofatso Setilo, Director Access, Prof Prakash Naidoo, Vice-Rector Operations
Prof Francis Petersen, Prof Daniella Coetzee (Principal: South Campus), Tshegofatso Setilo (Head: Access Programmes), and Prof Prakash Naidoo (Vice-Rector: Operations) on the South Campus for the welcoming of first-years.


“Welcome to the South Campus of the University of the Free State!” Addressing a packed Madiba Arena, Prof Francis Petersen, Rector and Vice-Chancellor of the UFS, said he was happy to see not only first-year students, but also parents and guardians, student leadership, and support staff from both the Bloemfontein and South Campuses.

 “I would like to congratulate each of our first-year students for making the decision to come to Kovsies to further your studies here. But I would also like to thank you for making this choice,” he continued.

Prof Petersen further emphasised that the students’ experience and success as individuals are important to the UFS as an institution; therefore, academic and support staff are on hand to guide them through their journey to becoming well-rounded individuals. “We will surely take care of you,” said Prof Petersen. He also reassured parents and guardians that their loved ones would be well looked after.

The Rector also focused attention on the role of student-leadership structures, such as the newly-formed Institutional Student Representative Council (ISRC) and South Campus SRC, members of which were present in the audience. He thanked them for playing a key role in the student constituency, highlighting their support and guidance to help first-years cultivate a sense of belonging at the UFS.

Turning back to first-year students, Prof Petersen stated that they have the unique opportunity to study on a campus specifically focused on developing their full potential, a campus where they can realise their dreams. “Your arrival on the campus marks a new chapter in your life. This chapter is slightly different, as you are the author thereof. The previous chapters in your life were largely written by others—your parents, guardians, families, teachers, and others. You will now be the main author in the next chapter of your unique story.”

“At Kovsies, we believe in developing students in their totality as human beings, not just the academic side. May your time with us equip you to make a success of your life after university!”

Prof Petersen’s Message to First-year Students
  1. Take responsibility for your academic programme.
    • Keep your focus. Study and study hard. You will reap the rewards and see the advantages of making success in your studies a top priority.
    • Make sure that you have enough time for your studies; balance your social life and your time set aside to study.
  2. Realise and remember that you are not alone.
    • If you find things difficult, seek help.
    • Our Department of Student Counselling and Development has trained staff and tailor-made programmes that can assist you.
    • Look after your mental health—and look after each other’s mental health.
  3. Make the most of your time at Kovsies.
    • Join one or more of the student organisations; why not try something new?
  4. Embrace difference and diversity.
    • Get to know students who are different from you.
    • You will lose valuable opportunities to grow if you only associate with your own all the time. It is important to get to know students who are different from you. It could be someone from a different part of the country, or from another country, a different ethnicity, a different religion, someone who has different views from yours, or who has different interests and perspectives.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept